This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Sirnaomics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Sirnaomics's earnings have been declining at an average annual rate of -2.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 37.9% per year.
Belangrijke informatie
-2.7%
Groei van de winst
30.3%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.0% |
| Inkomstengroei | 37.9% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -7,587.8% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Sirnaomics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -82 | 23 | 38 |
| 31 Mar 24 | 1 | -80 | 23 | 46 |
| 31 Dec 23 | 0 | -79 | 23 | 54 |
| 30 Sep 23 | 0 | -82 | 24 | 60 |
| 30 Jun 23 | 0 | -84 | 24 | 66 |
| 31 Mar 23 | 0 | -86 | 24 | 67 |
| 31 Dec 22 | 1 | -88 | 24 | 68 |
| 30 Sep 22 | 1 | -230 | 25 | 69 |
| 30 Jun 22 | 1 | -223 | 22 | 60 |
| 31 Mar 22 | 0 | -218 | 19 | 51 |
| 31 Dec 21 | 0 | -213 | 16 | 41 |
| 30 Sep 21 | 0 | -60 | 10 | 27 |
| 31 Dec 20 | 0 | -44 | 5 | 15 |
| 31 Dec 19 | 0 | -16 | 5 | 10 |
Kwaliteitswinsten: 2257 is currently unprofitable.
Groeiende winstmarge: 2257 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 2257 is unprofitable, and losses have increased over the past 5 years at a rate of 2.7% per year.
Versnelling van de groei: Unable to compare 2257's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 2257 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.7%).
Rendement op eigen vermogen
Hoge ROE: 2257's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.